Baotou Dongbao Bio-Tech Co Ltd (SHE:300239) — Market Cap & Net Worth
Market Cap & Net Worth: Baotou Dongbao Bio-Tech Co Ltd (300239)
Baotou Dongbao Bio-Tech Co Ltd (SHE:300239) has a market capitalization of $482.96 Million (CN¥3.30 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #12715 globally and #3970 in its home market, demonstrating a 5.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Baotou Dongbao Bio-Tech Co Ltd's stock price CN¥5.56 by its total outstanding shares 593607933 (593.61 Million). Analyse 300239 cash generation efficiency to see how efficiently the company converts income to cash.
Baotou Dongbao Bio-Tech Co Ltd Market Cap History: 2015 to 2026
Baotou Dongbao Bio-Tech Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $779.09 Million to $482.96 Million (-1.49% CAGR).
Baotou Dongbao Bio-Tech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Baotou Dongbao Bio-Tech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Baotou Dongbao Bio-Tech Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.32x
Baotou Dongbao Bio-Tech Co Ltd's market cap is 6.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $779.09 Million | $291.92 Million | $5.89 Million | 2.67x | 132.28x |
| 2016 | $679.71 Million | $316.59 Million | $19.23 Million | 2.15x | 35.35x |
| 2017 | $445.87 Million | $356.24 Million | $22.42 Million | 1.25x | 19.89x |
| 2018 | $314.19 Million | $452.75 Million | $33.98 Million | 0.69x | 9.25x |
| 2019 | $430.90 Million | $491.82 Million | $35.61 Million | 0.88x | 12.10x |
| 2020 | $512.91 Million | $448.83 Million | $18.45 Million | 1.14x | 27.80x |
| 2021 | $606.72 Million | $612.17 Million | $36.48 Million | 0.99x | 16.63x |
| 2022 | $646.00 Million | $943.40 Million | $109.44 Million | 0.68x | 5.90x |
| 2023 | $538.79 Million | $974.51 Million | $119.89 Million | 0.55x | 4.49x |
| 2024 | $543.77 Million | $884.93 Million | $85.98 Million | 0.61x | 6.32x |
Competitor Companies of 300239 by Market Capitalization
Companies near Baotou Dongbao Bio-Tech Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Baotou Dongbao Bio-Tech Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Baotou Dongbao Bio-Tech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Baotou Dongbao Bio-Tech Co Ltd's market cap moved from $779.09 Million to $ 482.96 Million, with a yearly change of -1.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥482.96 Million | -5.12% |
| 2025 | CN¥509.02 Million | -6.39% |
| 2024 | CN¥543.77 Million | +0.92% |
| 2023 | CN¥538.79 Million | -16.60% |
| 2022 | CN¥646.00 Million | +6.47% |
| 2021 | CN¥606.72 Million | +18.29% |
| 2020 | CN¥512.91 Million | +19.03% |
| 2019 | CN¥430.90 Million | +37.14% |
| 2018 | CN¥314.19 Million | -29.53% |
| 2017 | CN¥445.87 Million | -34.40% |
| 2016 | CN¥679.71 Million | -12.76% |
| 2015 | CN¥779.09 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Baotou Dongbao Bio-Tech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $482.96 Million USD |
| MoneyControl | $482.96 Million USD |
| MarketWatch | $482.96 Million USD |
| marketcap.company | $482.96 Million USD |
| Reuters | $482.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen and their derivative products in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private la… Read more